NCT03302078View on ClinicalTrials.gov

Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

December 13, 2017

Study Completion Date

December 13, 2017

Conditions
Healthy
Interventions
DRUG

BI 1015550

Fed state

DRUG

BI 1015550

Fasted state

Trial Locations (1)

88397

Humanpharmakologisches Zentrum Biberach, Biberach

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY